Search

Your search keyword '"Jones-Brando L"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Jones-Brando L" Remove constraint Author: "Jones-Brando L"
49 results on '"Jones-Brando L"'

Search Results

2. Sulforaphane exhibits in vitro and in vivo antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses

12. Transactivation of elements in the human endogenous retrovirus W family by viral infection

13. Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice.

14. Sulforaphane exhibits in vitro and in vivo antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses.

15. Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophrenia.

16. Latent infection, inflammatory markers and suicide attempt history in depressive disorders.

17. Atypical immune response to Epstein-Barr virus in major depressive disorder.

18. Host-parasite interaction associated with major mental illness.

19. Association of Cytomegalovirus and Toxoplasma gondii Antibody Titers With Bipolar Disorder.

20. Schizophrenia is Associated With an Aberrant Immune Response to Epstein-Barr Virus.

21. Aggression, impulsivity and inflammatory markers as risk factors for suicidal behavior.

22. Longitudinal serological measures of common infection in the Avon Longitudinal Study of Parents and Children cohort.

23. AAH2 gene is not required for dopamine-dependent neurochemical and behavioral abnormalities produced by Toxoplasma infection in mouse.

24. One-pot, multicomponent synthesis of 2,3-disubstituted quinazolin-ones with potent and selective activity against Toxoplasma gondii.

25. Synthesis and biological evaluation of anti-Toxoplasma gondii activity of a novel scaffold of thiazolidinone derivatives.

26. Enol ethers as carbonyl surrogates in a modification of the Povarov synthesis of 3-aryl quinolines and their anti-Toxoplasma activity.

27. Infection and characterization of Toxoplasma gondii in human induced neurons from patients with brain disorders and healthy controls.

28. Toxoplasma gondii-A Gastrointestinal Pathogen Associated with Human Brain Diseases.

29. Synthesis of the cyanobacterial metabolite nostodione A, structural studies and potent antiparasitic activity against Toxoplasma gondii.

30. Reply to Kjartansdóttir et al.: Chlorovirus ATCV-1 findings not explained by contamination.

31. Chlorovirus ATCV-1 is part of the human oropharyngeal virome and is associated with changes in cognitive functions in humans and mice.

32. Design, synthesis and biological characterization of thiazolidin-4-one derivatives as promising inhibitors of Toxoplasma gondii.

33. One minute ultraviolet exposure inhibits Toxoplasma gondii tachyzoite replication and cyst conversion without diminishing host humoral-mediated immune response.

34. A thiazole derivative of artemisinin moderately reduces Toxoplasma gondii cyst burden in infected mice.

35. Transcriptional derepression of the ERVWE1 locus following influenza A virus infection.

36. Synthesis and anti-toxoplasmosis activity of 4-arylquinoline-2-carboxylate derivatives.

37. Abnormalities of neurotransmitter and neuropeptide systems in human neuroepithelioma cells infected by three Toxoplasma strains.

38. Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis.

39. Differential effects of three canonical Toxoplasma strains on gene expression in human neuroepithelial cells.

40. Toxoplasma gondii strain-dependent effects on mouse behaviour.

41. Thiazole, oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondii.

42. Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers.

43. Synthesis and evaluation of 4-acyl-2-thiazolylhydrazone derivatives for anti-Toxoplasma efficacy in vitro.

44. Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle.

45. Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs.

46. In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin.

47. Altered transcriptional activity of human endogenous retroviruses in neuroepithelial cells after infection with Toxoplasma gondii.

48. Transactivation of elements in the human endogenous retrovirus W family by viral infection.

49. Infectious pathogen detection arrays: viral detection in cell lines and postmortem brain tissue.

Catalog

Books, media, physical & digital resources